Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Breast 2Tumor-Agnostic 1Lymphoid 1Gynecologic 1Genitourinary 1

Conditions

Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Breast Neoplasms 1

Interventions

Paclitaxel 77pembrolizumab 59Carboplatin 57Bevacizumab 57Specimen Handling 48Magnetic Resonance Spectroscopy 39Cisplatin 32olaparib 31Gemcitabine 25liposomal doxorubicin 24Biopsy 20Taxes 19Topotecan 17Nivolumab 17Cyclophosphamide 16Immunoglobulin G 15Doxorubicin 15Disulfides 15niraparib 12fludarabine 12Surveys and Questionnaires 12Letrozole 12lenvatinib 11durvalumab 11atezolizumab 11Fulvestrant 10Drug Therapy 10abemaciclib 9Docetaxel 9Brachytherapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
CX 5461 × Gynecologic × 90 days × Clear all
NCT04890613 2026-06-08

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Senhwa Biosciences, Inc.

Phase 1 Recruiting
52 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡